-- EXp World (EXPI) 週四宣布已收購全國性房地產特許經營公司 NextHome。 該公司補充道，NextHome 擁有遍布全美 500 多家加盟商，其可擴展的特許經營模式將為 EXp World 的生態系統注入新的活力。 該公司表示，伴隨此次收購，其股票將於週五開盤後在納斯達克以新代碼「AGNT」進行交易。 週四交易中，該公司股價上漲超過 4%。
Price: $6.78, Change: $+0.26, Percent Change: +3.91%
Related Articles
Sectors
Sector Update: Consumer Stocks Edge Lower Late Afternoon
Consumer stocks were edging down late Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) each decreasing 0.1%.In corporate news, Tapestry (TPR) raised its fiscal 2026 outlook after delivering a Q3 beat, but provided a subdued Q4 sales guidance for its Kate Spade brand. Its shares dropped more than 13%.Shake Shack (SHAK) shares slumped 28% after the company's Q1 results missed Wall Street estimates.Planet Fitness (PLNT) shares tumbled 32% after the company tempered its full-year outlook amid fewer-than-expected member additions in Q1.McDonald's (MCD) reported better-than-expected Q1 results as comparable sales rebounded more than market estimates despite what the company described as a "challenging" environment. Its shares rose 0.3%.
$MCD$PLNT$SHAK$TPR
Sectors
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.2%.In corporate news, Entrada Therapeutics (TRDA) shares tumbled 57% after its drug for children with Duchenne muscular dystrophy fell short of analyst expectations in an early-to-mid stage trial, Reuters reported Thursday.Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5.5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.1% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.
$CPRX$HRMY$IOVA$TRDA
Research
Cascades Target Eased To C$13 From $14, Keeps Sector Perform at National Bk Which Notes Q1 In Line With Reduced Outlook, Soft Q2 Outlook Before Recovery, Asset Sales Done By Q3
Price: $10.72, Change: $-0.23, Percent Change: -2.10%
$CAS.TO